The major objective of the Biostatistics and Bioinformatics Core (Core 3) is to provide centralized biostatistics, bioinformatics, and database support for all Projects and Cores. Core 3 will provide guidance in the design and conduct of clinical trials and other experiments that arise from the ongoing research of the SPORE, facilitate prospective collection, entry, quality control, and integration of data for the basic science, pre-clinical, and clinical studies, and provide bioinformatics data analysis of high-throughput and high-dimensional genomics data. We will provide innovative and tailored statistical modeling, simulation techniques, and data analyses for the main projects, developmental research and career enhancement projects, and other cores to achieve their specific aims. We will conduct data analyses and prepare statistical reports for all experiments within all projects, ensure that the results of all projects are appropriately interpreted, and assist all project investigators in the publication of scientific results. Core 3 will also be a resource for intra- and inter-SPORE collaborations, including study design and developing databases for multi-center clinical trials.

Public Health Relevance

The Biostatistics and Bioinformatics Core provides consultation and collaboration in the design, conduct, analysis, and interpretation of research studies in this SPORE, helps them achieve their objectives and ensures scientifically valid conclusions will be drawn. Effective formulation and application of efficacy, futility and safety monitoring rules for clinical trials will offer protection to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-18
Application #
10006810
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-08-05
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Takahashi, Koichi; Wang, Feng; Morita, Kiyomi et al. (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Kayser, Sabine; Levis, Mark J (2018) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol 180:484-500
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12

Showing the most recent 10 out of 487 publications